Genetics and genotypes in irritable bowel syndrome

Implications for diagnosis and treatment

Moo In Park, Michael Camilleri

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Several twin studies and familial aggregation studies in IBS are consistent with either a genetic or a social learning hypothesis, and it is possible that both play a role. The prospect of identifying a genetic cause for IBS may be very important, because it raises the possibility of confirming that IBS is a disease entity, suggests new insight into the pathophysiology of the disorder, and provides new targets for drug development. Several candidate genetic markers including: those related to cytokines such as IL-10, TNF-α and TGF β1; SERT-P; alpha-adrenergic receptors; and G proteins have been associated with certain aspects of IBS. Genetic polymorphisms, however, are common and may have no etiological or pathogenetic relevance. Searching for the genes in IBS is of potentially great relevance. Such studies may identify more specific phenotypes in IBS or potentially predict increased disease vulnerability, but it is unlikely that this strategy will lead to a diagnostic test, given the limited component of IBS that is likely to be genetically determined. Pharmacogenomic studies have potential to be important in the future. For this potential to be realized, it will be necessary to formally include genetic studies in trials of experimental drugs. This would enhance understanding of one of the roles of genetics for treating IBS.

Original languageEnglish (US)
Pages (from-to)305-317
Number of pages13
JournalGastroenterology Clinics of North America
Volume34
Issue number2 SPEC. ISS.
DOIs
StatePublished - Jun 2005

Fingerprint

Irritable Bowel Syndrome
Genotype
Receptors, Adrenergic, alpha
Twin Studies
Genetic Polymorphisms
Genetic Markers
GTP-Binding Proteins
Routine Diagnostic Tests
Pharmaceutical Preparations
Interleukin-10
Cytokines
Phenotype
Genes
Pharmacogenomic Testing
Social Learning

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Genetics and genotypes in irritable bowel syndrome : Implications for diagnosis and treatment. / Park, Moo In; Camilleri, Michael.

In: Gastroenterology Clinics of North America, Vol. 34, No. 2 SPEC. ISS., 06.2005, p. 305-317.

Research output: Contribution to journalArticle

@article{36991d59c51c465681c7ccd8280d1ea0,
title = "Genetics and genotypes in irritable bowel syndrome: Implications for diagnosis and treatment",
abstract = "Several twin studies and familial aggregation studies in IBS are consistent with either a genetic or a social learning hypothesis, and it is possible that both play a role. The prospect of identifying a genetic cause for IBS may be very important, because it raises the possibility of confirming that IBS is a disease entity, suggests new insight into the pathophysiology of the disorder, and provides new targets for drug development. Several candidate genetic markers including: those related to cytokines such as IL-10, TNF-α and TGF β1; SERT-P; alpha-adrenergic receptors; and G proteins have been associated with certain aspects of IBS. Genetic polymorphisms, however, are common and may have no etiological or pathogenetic relevance. Searching for the genes in IBS is of potentially great relevance. Such studies may identify more specific phenotypes in IBS or potentially predict increased disease vulnerability, but it is unlikely that this strategy will lead to a diagnostic test, given the limited component of IBS that is likely to be genetically determined. Pharmacogenomic studies have potential to be important in the future. For this potential to be realized, it will be necessary to formally include genetic studies in trials of experimental drugs. This would enhance understanding of one of the roles of genetics for treating IBS.",
author = "Park, {Moo In} and Michael Camilleri",
year = "2005",
month = "6",
doi = "10.1016/j.gtc.2005.02.009",
language = "English (US)",
volume = "34",
pages = "305--317",
journal = "Gastroenterology Clinics of North America",
issn = "0889-8553",
publisher = "W.B. Saunders Ltd",
number = "2 SPEC. ISS.",

}

TY - JOUR

T1 - Genetics and genotypes in irritable bowel syndrome

T2 - Implications for diagnosis and treatment

AU - Park, Moo In

AU - Camilleri, Michael

PY - 2005/6

Y1 - 2005/6

N2 - Several twin studies and familial aggregation studies in IBS are consistent with either a genetic or a social learning hypothesis, and it is possible that both play a role. The prospect of identifying a genetic cause for IBS may be very important, because it raises the possibility of confirming that IBS is a disease entity, suggests new insight into the pathophysiology of the disorder, and provides new targets for drug development. Several candidate genetic markers including: those related to cytokines such as IL-10, TNF-α and TGF β1; SERT-P; alpha-adrenergic receptors; and G proteins have been associated with certain aspects of IBS. Genetic polymorphisms, however, are common and may have no etiological or pathogenetic relevance. Searching for the genes in IBS is of potentially great relevance. Such studies may identify more specific phenotypes in IBS or potentially predict increased disease vulnerability, but it is unlikely that this strategy will lead to a diagnostic test, given the limited component of IBS that is likely to be genetically determined. Pharmacogenomic studies have potential to be important in the future. For this potential to be realized, it will be necessary to formally include genetic studies in trials of experimental drugs. This would enhance understanding of one of the roles of genetics for treating IBS.

AB - Several twin studies and familial aggregation studies in IBS are consistent with either a genetic or a social learning hypothesis, and it is possible that both play a role. The prospect of identifying a genetic cause for IBS may be very important, because it raises the possibility of confirming that IBS is a disease entity, suggests new insight into the pathophysiology of the disorder, and provides new targets for drug development. Several candidate genetic markers including: those related to cytokines such as IL-10, TNF-α and TGF β1; SERT-P; alpha-adrenergic receptors; and G proteins have been associated with certain aspects of IBS. Genetic polymorphisms, however, are common and may have no etiological or pathogenetic relevance. Searching for the genes in IBS is of potentially great relevance. Such studies may identify more specific phenotypes in IBS or potentially predict increased disease vulnerability, but it is unlikely that this strategy will lead to a diagnostic test, given the limited component of IBS that is likely to be genetically determined. Pharmacogenomic studies have potential to be important in the future. For this potential to be realized, it will be necessary to formally include genetic studies in trials of experimental drugs. This would enhance understanding of one of the roles of genetics for treating IBS.

UR - http://www.scopus.com/inward/record.url?scp=18144426823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144426823&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2005.02.009

DO - 10.1016/j.gtc.2005.02.009

M3 - Article

VL - 34

SP - 305

EP - 317

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 2 SPEC. ISS.

ER -